Literature DB >> 12130661

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.

Klaus Okkenhaug1, Antonio Bilancio, Géraldine Farjot, Helen Priddle, Sara Sancho, Emma Peskett, Wayne Pearce, Stephen E Meek, Ashreena Salpekar, Michael D Waterfield, Andrew J H Smith, Bart Vanhaesebroeck.   

Abstract

Class IA phosphoinositide 3-kinases (PI3Ks) are a family of p85/p110 heterodimeric lipid kinases that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metabolism, growth, proliferation, differentiation, motility, and survival. Mammals express three class IA catalytic subunits: p110alpha, p110beta, and p110delta. It is unclear to what extent these p110 isoforms have overlapping or distinct biological roles. Mice expressing a catalytically inactive form of p110delta (p110delta(D910A)) were generated by gene targeting. Antigen receptor signaling in B and T cells was impaired and immune responses in vivo were attenuated in p110delta mutant mice. They also developed inflammatory bowel disease. These results reveal a selective role for p110delta in immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130661     DOI: 10.1126/science.1073560

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  369 in total

Review 1.  Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Authors:  Qi-Wen Fan; William A Weiss
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.

Authors:  G V Baracho; A V Miletic; S A Omori; M H Cato; R C Rickert
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

3.  Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

Authors:  Shiann-Tarng Jou; Nick Carpino; Yutaka Takahashi; Roland Piekorz; Jyh-Rong Chao; Neena Carpino; Demin Wang; James N Ihle
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

Review 5.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 6.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Authors:  De-xin Kong; Takao Yamori
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

7.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 9.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

Review 10.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.